GlassScriptPhysician profile
Brian J Finley
NPI 1144278482
$20,380.79
in general payments reported to CMS, 2019-2025
72 companies · $3,216 in 2025
The $3,216 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,618 · 2020: $1,885 · 2021: $2,954 · 2022: $2,988 · 2023: $3,111 · 2024: $3,608 · 2025: $3,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,908 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,908.36 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,480.91 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,337.03 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Lilly USA, LLC | $1,535.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,200.17 | 2019-2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,077.09 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $934.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $901.28 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $851.72 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $731.66 | 2019-2023 | Xarelto |
| Pfizer INC. | $626.26 | 2019-2025 | |
| Allergan, INC. | $602.08 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $483.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $447.82 | 2019-2024 | Xifaxan |
| Lundbeck LLC | $403.42 | 2020-2025 | Vyepti, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $362.82 | 2022-2025 | Cobenfy |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Finley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.